Jerome Hauer - Emergent Biosolutions Independent Director
| EBS Stock | USD 10.46 0.42 3.86% |
Director
Dr. Jerome M. Hauer, Ph.D., is an Independent Director of the Company. He previously served on our Board of Directors from May 2004 to October 2011. Currently, Dr. Hauer is a senior advisor at Teneo Risk in New York City and Washington, D.C. and a visiting professor at Cranfield UniversityDefence Academy of the United Kingdom. Before joining Teneo Risk, Dr. Hauer served from January 2012 until December 2014 as the Commissioner of New York State Division of Homeland Security and Emergency Services and Chairman of the Executive Committee on Counterterrorism. Formerly, Dr. Hauer served as chief executive officer of The Hauer Group from 2006 to 2011 and as senior vice president and cochair of the homeland security practice of FleishmanHillard Government Relations from January 2005 to March 2006. Prior to joining FleishmanHillard, Dr. Hauer served as acting assistant secretary for the office of public health emergency preparedness at HHS from June 2002 to November 2003 and as director of the office of public health preparedness of HHS from May 2002 to June 2002. Dr. Hauer served as the first director of the New York City Mayor Office of Emergency Management under Mayor Rudolph Giuliani. He also served as the director of Emergency Medical Services and Emergency Management as well as director of the Department of Fire and Buildings for the State of Indiana under Governor Evan Bayh since 2015.
| Age | 68 |
| Tenure | 10 years |
| Professional Marks | Ph.D |
| Address | 400 Professional Drive, Gaithersburg, MD, United States, 20879 |
| Phone | 240 631 3200 |
| Web | https://www.emergentbiosolutions.com |
Emergent Biosolutions Management Efficiency
The company has Return on Asset of (0.0422) % which means that on every $100 spent on assets, it lost $0.0422. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of (0.3464) %, meaning that it generated no profit with money invested by stockholders. Emergent Biosolutions' management efficiency ratios could be used to measure how well Emergent Biosolutions manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to gain to -0.66 in 2025. Return On Capital Employed is likely to gain to -0.68 in 2025. At this time, Emergent Biosolutions' Non Currrent Assets Other are comparatively stable compared to the past year. Other Assets is likely to gain to about 231 M in 2025, whereas Non Current Assets Total are likely to drop slightly above 799.2 M in 2025.Similar Executives
| Showing other executives | DIRECTOR Age | ||
| John Byom | Prestige Brand Holdings | 66 | |
| Russel Robertson | Bausch Health Companies | 72 | |
| Gregory Norden | Zoetis Inc | 62 | |
| Thomas Ross | Bausch Health Companies | 69 | |
| Frank DAmelio | Zoetis Inc | 63 | |
| Robert Power | Bausch Health Companies | 63 | |
| Willie Reed | Zoetis Inc | 65 | |
| Amy Wechsler | Bausch Health Companies | 50 | |
| Celeste Clark | Prestige Brand Holdings | 67 | |
| Natale Ricciardi | Prestige Brand Holdings | 71 | |
| Gary Costley | Prestige Brand Holdings | 55 | |
| Dawn Zier | Prestige Brand Holdings | 55 | |
| Linda Rhodes | Zoetis Inc | 70 | |
| Sarah Kavanagh | Bausch Health Companies | 63 | |
| Argeris Karabelas | Bausch Health Companies | 66 | |
| James Jenness | Prestige Brand Holdings | 73 | |
| Antoinette Leatherberry | Zoetis Inc | 58 | |
| Andrew Eschenbach | Bausch Health Companies | 78 | |
| Paul Bisaro | Zoetis Inc | 59 | |
| Louise Parent | Zoetis Inc | 69 | |
| Richard Schutter | Bausch Health Companies | 79 | |
Management Performance
| Return On Equity | -0.35 | ||||
| Return On Asset | -0.0422 |
Emergent Biosolutions Leadership Team
Elected by the shareholders, the Emergent Biosolutions' board of directors comprises two types of representatives: Emergent Biosolutions inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Emergent. The board's role is to monitor Emergent Biosolutions' management team and ensure that shareholders' interests are well served. Emergent Biosolutions' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Emergent Biosolutions' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Kelly Warfield, Senior Development | ||
| Sean Kirk, Executive Vice President - Manufacturing and Technical Operations | ||
| William Hartzel, Senior Bioservices | ||
| Robert Burrows, IR Contact Officer | ||
| Stephanie Duatschek, Chief VP | ||
| Sue Bailey, Independent Director | ||
| Jerome Hauer, Independent Director | ||
| Haywood Miller, Interim Officer | ||
| Kathryn Zoon, Independent Director | ||
| Seamus Mulligan, Director | ||
| George Joulwan, Independent Director | ||
| Karen Smith, Executive Vice President Chief Medical Officer | ||
| Paul Williams, Senior Business | ||
| Keith Katkin, Independent Director | ||
| Simon MD, Chief Development | ||
| Jessica Perl, Corporate Counsel | ||
| Robert Kramer, CFO, Interim Executive Vice President - Corporate Services Division, Principal Financial and Accounting Officer, Treasurer | ||
| Richard MBA, CFO VP | ||
| Jennifer Fox, Executive Vice President - External Affairs, General Counsel, Corporate Secretary | ||
| Katherine Strei, Executive Vice President - Human Resources and Communications, Chief Human Resources Officer | ||
| Michelle Pepin, Senior Officer | ||
| Fuad ElHibri, Executive Chairman of the Board | ||
| Coleen Glessner, Executive Compliance | ||
| Lynn Kieffer, VP Communications | ||
| Joseph Papa, CEO President | ||
| Marvin White, Director | ||
| Atul Saran, Executive Vice President Corporate Development, General Counsel and Corporate Secretary | ||
| Robert Sr, Pres CEO | ||
| Adam Havey, Executive VP and President of Biodefense Division | ||
| Louis Sullivan, Independent Director | ||
| Ronald Richard, Lead Independent Director | ||
| Zsolt Harsanyi, Non-Executive Independent Chairman of the Board | ||
| Richard Lindahl, Chief Financial Officer, Executive Vice President, Treasurer |
Emergent Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Emergent Biosolutions a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.35 | ||||
| Return On Asset | -0.0422 | ||||
| Profit Margin | (0.19) % | ||||
| Operating Margin | 0.25 % | ||||
| Current Valuation | 1.1 B | ||||
| Shares Outstanding | 54.18 M | ||||
| Shares Owned By Insiders | 2.15 % | ||||
| Shares Owned By Institutions | 57.78 % | ||||
| Number Of Shares Shorted | 6.95 M | ||||
| Price To Earning | 1.67 X |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Emergent Stock Analysis
When running Emergent Biosolutions' price analysis, check to measure Emergent Biosolutions' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Emergent Biosolutions is operating at the current time. Most of Emergent Biosolutions' value examination focuses on studying past and present price action to predict the probability of Emergent Biosolutions' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Emergent Biosolutions' price. Additionally, you may evaluate how the addition of Emergent Biosolutions to your portfolios can decrease your overall portfolio volatility.